Movement Alert｜HENGRUI PHARMA Intraday Rise 3.19% in Regular Trading, earnings window, share buybacks and pipeline updates support sentiment

Market Focus10-20

On October 20, HENGRUI PHARMA recorded an Intraday Rise of 3.19% in Regular Trading, with the stock trading at HK$49.22 and turnover reaching HK$73.53 million.

The most direct catalyst in public information was a same-day market update linking the move to the approaching October 27 board meeting on the first nine months results, recent A-share buybacks, and fresh pipeline progress.

In the latest disclosed buyback, the company repurchased 203,600 A shares on October 19 for about RMB9.40 million at RMB46.08 to RMB46.21 per share, following repurchases of 195,000 shares for RMB9.00 million on October 16 and 442,600 shares for about RMB20.00 million on October 13, with the shares intended for an employee shareholding plan. On the pipeline side, its AD candidate SHR-3201 received approval to start clinical trials in China, while fluzoparib was accepted by the EMA for review. Public previews ahead of the October 27 results note no clear consensus forecast, but institutional views remain cautiously constructive on innovative drug sales growth offsetting pricing pressure.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1123042514?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-10-20 10:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1123042514","market":"us","top_or_hot":-1,"title":"Movement Alert｜HENGRUI PHARMA Intraday Rise 3.19% in Regular Trading, earnings window, share buybacks and pipeline updates support sentiment","media":"Market Focus","content":"<p><p>On October 20, HENGRUI PHARMA recorded an Intraday Rise of 3.19% in Regular Trading, with the stock trading at HK$49.22 and turnover reaching HK$73.53 million.</p><p>The most direct catalyst in public information was a same-day market update linking the move to the approaching October 27 board meeting on the first nine months results, recent A-share buybacks, and fresh pipeline progress.</p><p>In the latest disclosed buyback, the company repurchased 203,600 A shares on October 19 for about RMB9.40 million at RMB46.08 to RMB46.21 per share, following repurchases of 195,000 shares for RMB9.00 million on October 16 and 442,600 shares for about RMB20.00 million on October 13, with the shares intended for an employee shareholding plan. On the pipeline side, its AD candidate SHR-3201 received approval to start clinical trials in China, while fluzoparib was accepted by the EMA for review. Public previews ahead of the October 27 results note no clear consensus forecast, but institutional views remain cautiously constructive on innovative drug sales growth offsetting pricing pressure.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜HENGRUI PHARMA Intraday Rise 3.19% in Regular Trading, earnings window, share buybacks and pipeline updates support sentiment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜HENGRUI PHARMA Intraday Rise 3.19% in Regular Trading, earnings window, share buybacks and pipeline updates support sentiment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-10-20 10:34</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On October 20, HENGRUI PHARMA recorded an Intraday Rise of 3.19% in Regular Trading, with the stock trading at HK$49.22 and turnover reaching HK$73.53 million.</p><p>The most direct catalyst in public information was a same-day market update linking the move to the approaching October 27 board meeting on the first nine months results, recent A-share buybacks, and fresh pipeline progress.</p><p>In the latest disclosed buyback, the company repurchased 203,600 A shares on October 19 for about RMB9.40 million at RMB46.08 to RMB46.21 per share, following repurchases of 195,000 shares for RMB9.00 million on October 16 and 442,600 shares for about RMB20.00 million on October 13, with the shares intended for an employee shareholding plan. On the pipeline side, its AD candidate SHR-3201 received approval to start clinical trials in China, while fluzoparib was accepted by the EMA for review. Public previews ahead of the October 27 results note no clear consensus forecast, but institutional views remain cautiously constructive on innovative drug sales growth offsetting pricing pressure.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01276","symbol_name":"恒瑞医药","start_time":0,"source_url":"","article_id":"1123042514","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1123042514","pubTimestamp":1792463647,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On October 20, HENGRUI PHARMA recorded an Intraday Rise of 3.19% in Regular Trading, with the stock trading at HK$49.22 and turnover reaching HK$73.53 million.The most direct catalyst in public...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01276":"恒瑞医药"},"translate_title":"走势提醒|恒瑞医药常规交易盘中上涨3.19%，盈利窗口、股票回购和管道更新支撑情绪","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01276":1},"content_text":"On October 20, HENGRUI PHARMA recorded an Intraday Rise of 3.19% in Regular Trading, with the stock trading at HK$49.22 and turnover reaching HK$73.53 million.The most direct catalyst in public information was a same-day market update linking the move to the approaching October 27 board meeting on the first nine months results, recent A-share buybacks, and fresh pipeline progress.In the latest disclosed buyback, the company repurchased 203,600 A shares on October 19 for about RMB9.40 million at RMB46.08 to RMB46.21 per share, following repurchases of 195,000 shares for RMB9.00 million on October 16 and 442,600 shares for about RMB20.00 million on October 13, with the shares intended for an employee shareholding plan. On the pipeline side, its AD candidate SHR-3201 received approval to start clinical trials in China, while fluzoparib was accepted by the EMA for review. Public previews ahead of the October 27 results note no clear consensus forecast, but institutional views remain cautiously constructive on innovative drug sales growth offsetting pricing pressure.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1123042514","isCrawlerRequest":true}